9 completed, 2 withdrawn, 1 active not recruiting, 1 enrolling by invitation. 11 Phase 2, 3 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 7, Withdrawn 2, Enrolling by invitation 1, Recruiting 1 |
| Phase 1 | 3 | Completed 2, Unknown 1 |
| Phase 3 | 3 | Completed 2, Active not recruiting 1 |
Follow ebselen: new trials by email Literature Review of ebselen trials Research Report on ebselen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SPI-1005 in Adults Receiving Cochlear Implant Ebselen, Placebo - Hearing Loss, Cochlear Trauma | Phase 2 | Recruiting | Sound Pharmaceuticals, Incorporated | 40 | 2026-12-01 | 2026-06-26 |
| SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss SPI-1005 Low Dose, SPI-1005 Middle Dose, SPI-1005 High Dose - Lung Cancer, Head and Neck Cancer | Phase 2 | Withdrawn | Sound Pharmaceuticals, Incorporated | 2026-06-01 | 2026-06-03 | |
| A Phase 2b Study of SPI-1005 to Prevent Acute Noise Induced Hearing Loss SPI-1005 200mg, SPI-1005 400mg, Placebo - Noise Induced Hearing Loss | Phase 2 | Withdrawn | Sound Pharmaceuticals, Incorporated | 2026-06-01 | 2026-06-03 | |
| SPI-1005 for the Treatment of Meniere's Disease (Open Label) Ebselen - Meniere's Disease, Ménière's Disease | Phase 3 | Active not recruiting | Sound Pharmaceuticals, Incorporated | 200 | 2025-10-29 | 2026-07-13 |
| SPI-1005 for the Treatment of Meniere's Disease Ebselen, Placebo - Meniere Disease, Ménière | Phase 3 | Completed | Sound Pharmaceuticals, Incorporated | 220 | 2022-08-02 | 2026-07-23 |
| SPI-1005 Treatment in Moderate COVID-19 Patients Ebselen, Placebo - Covid19, Corona Virus Infection | Phase 2 | Enrolling by invitation | Sound Pharmaceuticals, Incorporated | 60 | 2021-10-12 | 2023-10-03 |
| SPI-1005 Treatment in Severe COVID-19 Patients Ebselen, Placebo - Covid19, Coronavirus | Phase 2 | Completed | Sound Pharmaceuticals, Incorporated | 25 | 2021-08-27 | 2026-06-29 |
| IMPase in Treatment-resistant Depression Ebselen, Placebo - Depressive Disorder, Treatment-Resistant | Phase 1 | Unknown | University of Oxford | 50 | 2021-04-22 | 2023-07-06 |
| Ebselen as an add-on Treatment in Hypo/Mania Ebselen, Placebo oral capsule - Bipolar Disorder, Bipolar Disorder, Manic | Phase 2 | Completed | University of Oxford | 60 | 2017-10-01 | 2019-09-06 |
| SPI-1005 for the Treatment of Patients With Meniere's Disease 200mg SPI-1005 BID, 400mg SPI-1005 BID, Placebo - Meniere's Disease | Phase 2 | Completed | Sound Pharmaceuticals, Incorporated | 149 | 2017-09-28 | 2023-09-18 |
| SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity Placebo, SPI-1005 Ebselen 200mg Capsule x1, SPI-1005 Ebselen 200mg Capsule x2 - Ototoxicity | Phase 2 | Completed | Sound Pharmaceuticals, Incorporated | 35 | 2017-07-21 | 2026-07-16 |
| Study to Evaluate SPI-1005 in Adults With Meniere's Disease SPI-1005 - Meniere's Disease | Phase 1 / Phase 2 | Completed | Sound Pharmaceuticals, Incorporated | 40 | 2015-12-01 | 2026-06-29 |
| Otoprotection With SPI-1005 for Prevention of Temporary Auditory Threshold Shift SPI-1005 Low dose, SPI-1005 Middle dose, SPI-1005 High dose - Temporary Auditory Threshold Shift | Phase 2 | Completed | Sound Pharmaceuticals, Incorporated | 83 | 2011-09-01 | 2026-06-03 |
| Study to Evaluate the Safety and Pharmacokinetics of SPI-1005 SPI-1005, Placebo - Hearing Loss, Cancer | Phase 1 | Completed | Sound Pharmaceuticals, Incorporated | 32 | 2006-05-01 | 2016-06-29 |
| Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus Ebselen, Placebo - Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | Phase 2 / Phase 3 | Completed | Brigham and Women's Hospital | 60 | 1999-05-01 | 2008-09-30 |
| Expanded Access Protocol for SPI-1005 Ebselen - Meniere's Disease, Meniere Disease | Temporarily not available | Sound Pharmaceuticals, Incorporated | 2026-10-14 |
Hearing Loss (9) · Tinnitus (6) · Meniere Disease (5) · Vertigo (5) · COVID-19 (2) · Coronavirus Infections (2) · Deafness (2) · Dizziness (2) · Ototoxicity (2) · Bipolar Disorder (1) · Cystic Fibrosis (1) · Depressive Disorder, Treatment-Resistant (1) · Diabetes Mellitus, Type 1 (1) · Diabetes Mellitus, Type 2 (1) · Head and Neck Neoplasms (1)
Sound Pharmaceuticals, Incorporated (13) · University of Oxford (2) · Brigham and Women's Hospital (1)
United States (13) · United Kingdom (2)
Jonathan Kil, MD (6) · Miriam Treggiari, MD (2) · Philip J Cowen, MBBS, MD (2) · Colleen Le Prell, PhD (1) · James C. Kisicki, M.D. (1) · Mark A Creager, MD (1)
PMID 32483557, PMID 24975234, PMID 28716314, PMID 32909076, PMID 34510123
2015 (1)